<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="block">
            <roleset id="block.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="causer agent&#x0A;" />
                    <role n="1" descr="theme (process or entity being stopped)&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation might be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation were able to be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation were believed to be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation would be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine could block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine had blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine might block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine might have blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine was able to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine was believed to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine was believed to have blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>A downstream kinase appeared to be essential for agrin-mediated signaling, since staurosporine was blocking agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling because of staurosporines ability to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling because of staurosporines blocking agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation are able to be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation are believed to be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation are blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation can be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation have been blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation may be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation were blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since agrin-induced AChR clustering and phosphorylation will be blocked by staurosporine without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine can block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine has blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine is able to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine is believed to block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine is believed to have blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine is blocking agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine may block agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine may have blocked agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Alanine blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Alanine blocks the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Alanine can block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Alanine can have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Alanine could block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Alanine could have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>Alanine has blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>Alanine is able to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>Alanine is believed to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>Alanine may block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Alanine may have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Alanine might block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>Alanine might have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>Alanine was able to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Alanine was believed to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Alanine will block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Alanine would block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 are shown to be able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 are shown to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 are shown to have blocked merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 have been shown to be able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 have been shown to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Both RAP1 and 2 are important vaccine candidates because antibodies to RAP1 have been shown to have blocked merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 blocked merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 can block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 may block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 were able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro can be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro could be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro has been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro is believed to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro is blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro may be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro might be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro was believed to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro was blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro will be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that merozoite invasion in vitro would be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>Both RAP1 and 2 are important vaccine candidates because merozoite invasion in vitro is shown to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>Both RAP1 and 2 are important vaccine candidates because merozoite invasion in vitro is shown to have been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>Both RAP1 and 2 are important vaccine candidates because merozoite invasion in vitro was shown to be blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>Both RAP1 and 2 are important vaccine candidates because merozoite invasion in vitro was shown to have been blocked by antibodies to RAP1 (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>It blocked membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>It blocks membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>It can block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>It could block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>It has blocked membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>It is able to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>It is believed to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>It may block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>It might block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>It was able to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>It was believed to block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>It will block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>It would block membranes in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since labeling can be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since labeling is able to be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since labeling is believed to be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide blocks labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide can block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide can have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide is able to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide may block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide may have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since pre-incubation of the antibodies with the phosphopeptide will block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling could be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling has been blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling was able to be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling was believed to be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since labeling was blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide could block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide could have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide might block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide might have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide was able to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide would block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since pre-incubation of the antibodies with the phosphopeptide would have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Membranes are able to be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Membranes are believed to be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Membranes are blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Membranes can be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Membranes has been blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Membranes may be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Membranes will be blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Mutations at the 3 splice site being able to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Mutations at the 3 splice site believed to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>Mutations at the 3 splice site specifically blocking step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>Mutations at the 3 splice site that are able to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>Mutations at the 3 splice site that are believed to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>Mutations at the 3 splice site that are shown to specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>Mutations at the 3 splice site that can specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>Mutations at the 3 splice site that have specifically blocked step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>Mutations at the 3 splice site that may specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>Mutations at the 3 splice site that specifically blocked step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation blocks myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation can block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is believed to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is believed to have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is proven to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is proven to have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation can be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation is believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation is blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation may be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation will be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation has been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation was blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation can not block elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation is not able to block elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and elevation of GR by 14-3-3eta can not be blocked by inhibition of translation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and elevation of GR by 14-3-3eta is believed not to be blocked by inhibition of translation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and elevation of GR by 14-3-3eta is not able to be blocked by inhibition of translation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and elevation of GR by 14-3-3eta is not blocked by inhibition of translation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation does not block elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation has not blocked elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation will not block elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Step II can be specifically blocked by mutations at the 3 splice site which do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Step II is believed to be specifically blocked by mutations at the 3 splice site which do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Step II is specifically blocked by mutations at the 3 splice site which do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Step II was specifically blocked by mutations at the 3 splice site which do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because RNA polymerase during elongation can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because RNA polymerase during elongation is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because RNA polymerase during elongation is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because RNA polymerase during elongation was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because it blocked RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because it can block RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because it is able to block RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because it may blocks RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway blocking the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway by blocking the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway for blocking the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway that blocked the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway that have blocked the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>the action of a postulated repressor can be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>the action of a postulated repressor has been blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>the action of a postulated repressor is blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>the action of a postulated repressor was blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>A downstream kinase appears to be essential for agrin-mediated signaling, since staurosporine blocks agrin-induced AChR clustering and phosphorylation without inhibiting MuSK phosphorylation (Wallace, 1994; Fuhrer et al., 1997).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that antibodies to RAP1 are able to block merozoite invasion in vitro (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since labeling is blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="EMBO" no="4">
                    <text>Membranes were blocked in TBST (Tris-buffered saline, 0.05% Tween-20) containing 5% bovine serum albumin (for anti-phosphoryrosine blots) or skimmed milk and probed with antibodies.</text>
                    <arg n="1">Membranes</arg>
                </example>
                <example src="EMBO" no="5">
                    <text>Tagetin is more specific for distinguishing between different RNA polymerases because it blocks RNA polymerase during elongation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="GREC" no="1">
                    <text>Alanine is thought to act as an inducer to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="GREC" no="2">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="GREC" no="3">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of translation did not block elevation of GR by 14-3-3eta, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="GREC" no="4">
                    <text>These results suggest that 14-3-3eta functions as a positive regulator in the glucocorticoid signal pathway by blocking the degradation of GR and inducing an elevation of GR, thus enhancing the transcriptional activity of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>Mutations at the 3 splice site that specifically block step II do not affect the association of hPrps 16 and 17 with the spliceosome, indicating that these factors may function at a stage of step II prior to recognition of the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Alanine is more specific for distinguishing between different RNA polymerases because it blocked the action of a postulated repressor (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Alanine is more specific for distinguishing between different RNA polymerases because it blocks the action of a postulated repressor (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Alanine is more specific for distinguishing between different RNA polymerases because it can block the action of a postulated repressor (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Alanine is more specific for distinguishing between different RNA polymerases because it is able to block the action of a postulated repressor (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Alanine is more specific for distinguishing between different RNA polymerases because it may blocks the action of a postulated repressor (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Alanine is more specific for distinguishing between different RNA polymerases because the action of a postulated repressor can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Alanine is more specific for distinguishing between different RNA polymerases because the action of a postulated repressor is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Alanine is more specific for distinguishing between different RNA polymerases because the action of a postulated repressor is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Alanine is more specific for distinguishing between different RNA polymerases because the action of a postulated repressor was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Both RAP1 and 2 are important vaccine candidates because Alanine are shown to be able to block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Both RAP1 and 2 are important vaccine candidates because Alanine are shown to block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Both RAP1 and 2 are important vaccine candidates because Alanine are shown to have blocked the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Both RAP1 and 2 are important vaccine candidates because Alanine have been shown to be able to block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Both RAP1 and 2 are important vaccine candidates because Alanine have been shown to block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Both RAP1 and 2 are important vaccine candidates because Alanine have been shown to have blocked the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Both RAP1 and 2 are important vaccine candidates because RNA polymerase during elongation is shown to be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Both RAP1 and 2 are important vaccine candidates because RNA polymerase during elongation is shown to have been blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Both RAP1 and 2 are important vaccine candidates because RNA polymerase during elongation was shown to be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Both RAP1 and 2 are important vaccine candidates because RNA polymerase during elongation was shown to have been blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Both RAP1 and 2 are important vaccine candidates because Tagetin are shown to be able to block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Both RAP1 and 2 are important vaccine candidates because Tagetin are shown to block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Both RAP1 and 2 are important vaccine candidates because Tagetin are shown to have blocked RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Both RAP1 and 2 are important vaccine candidates because Tagetin have been shown to be able to block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Both RAP1 and 2 are important vaccine candidates because Tagetin have been shown to block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Both RAP1 and 2 are important vaccine candidates because Tagetin have been shown to have blocked RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Both RAP1 and 2 are important vaccine candidates because elevation of GR by 14-3-3eta is shown to be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Both RAP1 and 2 are important vaccine candidates because elevation of GR by 14-3-3eta is shown to have been blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Both RAP1 and 2 are important vaccine candidates because elevation of GR by 14-3-3eta was shown to be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Both RAP1 and 2 are important vaccine candidates because elevation of GR by 14-3-3eta was shown to have been blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation are shown to be able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation are shown to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation are shown to have blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation have been shown to be able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation have been shown to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation have been shown to have blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation are shown to be able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation are shown to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation are shown to have blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation have been shown to be able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation have been shown to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation have been shown to have blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of translation are shown to be able to block elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of translation are shown to block elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of translation are shown to have blocked elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of translation have been shown to be able to block elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of translation have been shown to block elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Both RAP1 and 2 are important vaccine candidates because inhibition of translation have been shown to have blocked elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Alanine are able to block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Alanine block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Alanine blocked the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Alanine can block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Alanine may block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Alanine were able to block the action of a postulated repressor (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation can be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation could be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation has been blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation is believed to be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation is blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation may be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation might be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation was believed to be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation was blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation will be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that RNA polymerase during elongation would be blocked by Tagetin (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Tagetin are able to block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Tagetin block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Tagetin blocked RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Tagetin can block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Tagetin may block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Tagetin were able to block RNA polymerase during elongation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta can be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta could be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta has been blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta is believed to be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta is blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta may be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta might be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta was believed to be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta was blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta will be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that elevation of GR by 14-3-3eta would be blocked by inhibition of translation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation are able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation can block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation may block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation were able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation are able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation blocked myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation can block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation may block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation were able to block myeloid colony formation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of translation are able to block elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of translation block elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of translation blocked elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of translation can block elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of translation may block elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that inhibition of translation were able to block elevation of GR by 14-3-3eta (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling can be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling could be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling has been blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling is believed to be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling is blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling may be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling might be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling was believed to be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling was blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling will be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that labeling would be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation can be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation can be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation could be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation could be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation has been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation has been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation is believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation is believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation is blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation is blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation may be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation may be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation might be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation might be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation was believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation was believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation was blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation was blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation will be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation will be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation would be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that myeloid colony formation would be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that pre-incubation of the antibodies with the phosphopeptide are able to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that pre-incubation of the antibodies with the phosphopeptide block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that pre-incubation of the antibodies with the phosphopeptide blocked labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that pre-incubation of the antibodies with the phosphopeptide can block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that pre-incubation of the antibodies with the phosphopeptide may block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that pre-incubation of the antibodies with the phosphopeptide were able to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor can be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor could be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor has been blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor is believed to be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor is blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor may be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor might be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor was believed to be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor was blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor will be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the action of a postulated repressor would be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Both RAP1 and 2 are important vaccine candidates because labeling is shown to be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Both RAP1 and 2 are important vaccine candidates because labeling is shown to have been blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Both RAP1 and 2 are important vaccine candidates because labeling was shown to be blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Both RAP1 and 2 are important vaccine candidates because labeling was shown to have been blocked by pre-incubation of the antibodies with the phosphopeptide (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Both RAP1 and 2 are important vaccine candidates because myeloid colony formation is shown to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Both RAP1 and 2 are important vaccine candidates because myeloid colony formation is shown to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Both RAP1 and 2 are important vaccine candidates because myeloid colony formation is shown to have been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Both RAP1 and 2 are important vaccine candidates because myeloid colony formation is shown to have been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Both RAP1 and 2 are important vaccine candidates because myeloid colony formation was shown to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Both RAP1 and 2 are important vaccine candidates because myeloid colony formation was shown to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Both RAP1 and 2 are important vaccine candidates because myeloid colony formation was shown to have been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Both RAP1 and 2 are important vaccine candidates because myeloid colony formation was shown to have been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Both RAP1 and 2 are important vaccine candidates because pre-incubation of the antibodies with the phosphopeptide are shown to be able to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Both RAP1 and 2 are important vaccine candidates because pre-incubation of the antibodies with the phosphopeptide are shown to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Both RAP1 and 2 are important vaccine candidates because pre-incubation of the antibodies with the phosphopeptide are shown to have blocked labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Both RAP1 and 2 are important vaccine candidates because pre-incubation of the antibodies with the phosphopeptide have been shown to be able to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Both RAP1 and 2 are important vaccine candidates because pre-incubation of the antibodies with the phosphopeptide have been shown to block labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Both RAP1 and 2 are important vaccine candidates because pre-incubation of the antibodies with the phosphopeptide have been shown to have blocked labeling (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Both RAP1 and 2 are important vaccine candidates because the action of a postulated repressor is shown to be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>Both RAP1 and 2 are important vaccine candidates because the action of a postulated repressor is shown to have been blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>Both RAP1 and 2 are important vaccine candidates because the action of a postulated repressor was shown to be blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>Both RAP1 and 2 are important vaccine candidates because the action of a postulated repressor was shown to have been blocked by Alanine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Alanine blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Alanine blocks the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Alanine can block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Alanine can have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Alanine have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Alanine is able to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Alanine may block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Alanine may have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Alanine will block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since RNA polymerase during elongation can be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since RNA polymerase during elongation is able to be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since RNA polymerase during elongation is believed to be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since RNA polymerase during elongation is blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Tagetin blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Tagetin blocks RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Tagetin can block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Tagetin can have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Tagetin have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Tagetin is able to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Tagetin may block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Tagetin may have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Tagetin will block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since antibodies to RAP1 blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since antibodies to RAP1 blocks merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since antibodies to RAP1 can block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since antibodies to RAP1 can have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since antibodies to RAP1 have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since antibodies to RAP1 is able to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since antibodies to RAP1 may block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since antibodies to RAP1 may have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since antibodies to RAP1 will block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since elevation of GR by 14-3-3eta can be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since elevation of GR by 14-3-3eta is able to be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since elevation of GR by 14-3-3eta is believed to be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since elevation of GR by 14-3-3eta is blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation can block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation can have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation may block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation may have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation blocks myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation can block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation can have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation may block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation may have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of translation blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of translation blocks elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of translation can block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of translation can have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of translation have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of translation is able to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of translation may block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of translation may have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since inhibition of translation will block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since merozoite invasion in vitro can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since merozoite invasion in vitro is able to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since merozoite invasion in vitro is believed to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since merozoite invasion in vitro is blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since myeloid colony formation can be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since myeloid colony formation can be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since myeloid colony formation is able to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since myeloid colony formation is able to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since myeloid colony formation is believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since myeloid colony formation is believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since myeloid colony formation is blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since myeloid colony formation is blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the action of a postulated repressor can be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the action of a postulated repressor is able to be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the action of a postulated repressor is believed to be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the action of a postulated repressor is blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Alanine could block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Alanine could have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Alanine might block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Alanine might have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Alanine was able to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Alanine would block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Alanine would have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since RNA polymerase during elongation could be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since RNA polymerase during elongation has been blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since RNA polymerase during elongation was able to be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since RNA polymerase during elongation was believed to be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since RNA polymerase during elongation was blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Tagetin could block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Tagetin could have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Tagetin might block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Tagetin might have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Tagetin was able to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Tagetin would block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Tagetin would have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since antibodies to RAP1 could block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since antibodies to RAP1 could have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since antibodies to RAP1 might block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since antibodies to RAP1 might have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since antibodies to RAP1 was able to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since antibodies to RAP1 would block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since antibodies to RAP1 would have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since elevation of GR by 14-3-3eta could be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since elevation of GR by 14-3-3eta has been blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since elevation of GR by 14-3-3eta was able to be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since elevation of GR by 14-3-3eta was believed to be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since elevation of GR by 14-3-3eta was blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation could block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation could have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation might block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation might have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation was able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation would block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation would have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation could block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation could have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation might block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation might have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation was able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation would block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation would have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of translation could block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of translation could have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of translation might block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of translation might have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of translation was able to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of translation would block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since inhibition of translation would have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since merozoite invasion in vitro could be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since merozoite invasion in vitro has been blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since merozoite invasion in vitro was able to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since merozoite invasion in vitro was believed to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since merozoite invasion in vitro was blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation could be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation could be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation has been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation has been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation was able to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation was able to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation was believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation was believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation was blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since myeloid colony formation was blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the action of a postulated repressor could be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the action of a postulated repressor has been blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the action of a postulated repressor was able to be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the action of a postulated repressor was believed to be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the action of a postulated repressor was blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine blocks the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine can block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine has blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine is able to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine is believed to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine is believed to have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine is proven to block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine is proven to have blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine will block the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and RNA polymerase during elongation can be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and RNA polymerase during elongation is believed to be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and RNA polymerase during elongation is blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and RNA polymerase during elongation may be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and RNA polymerase during elongation will be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin blocks RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin can block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin has blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin is able to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin is believed to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin is believed to have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin is proven to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin is proven to have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin will block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 blocks merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 can block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 has blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 is able to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 is believed to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 is believed to have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 is proven to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 is proven to have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 will block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and elevation of GR by 14-3-3eta can be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and elevation of GR by 14-3-3eta is believed to be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and elevation of GR by 14-3-3eta is blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and elevation of GR by 14-3-3eta may be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and elevation of GR by 14-3-3eta will be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation can block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is believed to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is believed to have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is proven to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is proven to have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation blocks elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation can block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation has blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation is able to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation is believed to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation is believed to have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation is proven to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation is proven to have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation will block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and labeling can be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and labeling is believed to be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and labeling is blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and labeling may be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and labeling will be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and merozoite invasion in vitro can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and merozoite invasion in vitro is believed to be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and merozoite invasion in vitro is blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and merozoite invasion in vitro may be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and merozoite invasion in vitro will be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation can be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation is believed to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation is blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation may be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation will be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide blocks labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide can block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide has blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide is able to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide is believed to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide is believed to have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide is proven to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide is proven to have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide will block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the action of a postulated repressor can be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the action of a postulated repressor is believed to be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the action of a postulated repressor is blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the action of a postulated repressor may be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the action of a postulated repressor will be blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and Alanine has blocked the action of a postulated repressor.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and RNA polymerase during elongation has been blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and RNA polymerase during elongation was blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and Tagetin has blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and antibodies to RAP1 has blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and elevation of GR by 14-3-3eta has been blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and elevation of GR by 14-3-3eta was blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of translation has blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and labeling has been blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and labeling was blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and merozoite invasion in vitro has been blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and merozoite invasion in vitro was blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation has been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and myeloid colony formation was blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and pre-incubation of the antibodies with the phosphopeptide has blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and the action of a postulated repressor has been blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and the action of a postulated repressor was blocked by Alanine.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Alanine can not block the action of a postulated repressor, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Alanine is not able to block the action of a postulated repressor, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Tagetin can not block RNA polymerase during elongation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Tagetin is not able to block RNA polymerase during elongation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and antibodies to RAP1 can not block merozoite invasion in vitro, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and antibodies to RAP1 is not able to block merozoite invasion in vitro, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation can not block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is not able to block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation can not block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is not able to block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and pre-incubation of the antibodies with the phosphopeptide can not block labeling, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and pre-incubation of the antibodies with the phosphopeptide is not able to block labeling, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Alanine did not block the action of a postulated repressor, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Tagetin did not block RNA polymerase during elongation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and antibodies to RAP1 did not block merozoite invasion in vitro, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation did not block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation did not block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and pre-incubation of the antibodies with the phosphopeptide did not block labeling, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Alanine does not block the action of a postulated repressor, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and RNA polymerase during elongation can not be blocked by Tagetin, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and RNA polymerase during elongation is believed not to be blocked by Tagetin, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and RNA polymerase during elongation is not able to be blocked by Tagetin, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and RNA polymerase during elongation is not blocked by Tagetin, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Tagetin does not block RNA polymerase during elongation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and antibodies to RAP1 does not block merozoite invasion in vitro, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation does not block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation does not block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and labeling can not be blocked by pre-incubation of the antibodies with the phosphopeptide, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and labeling is believed not to be blocked by pre-incubation of the antibodies with the phosphopeptide, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and labeling is not able to be blocked by pre-incubation of the antibodies with the phosphopeptide, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and labeling is not blocked by pre-incubation of the antibodies with the phosphopeptide, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and merozoite invasion in vitro can not be blocked by antibodies to RAP1, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and merozoite invasion in vitro is believed not to be blocked by antibodies to RAP1, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and merozoite invasion in vitro is not able to be blocked by antibodies to RAP1, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and merozoite invasion in vitro is not blocked by antibodies to RAP1, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and myeloid colony formation can not be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and myeloid colony formation can not be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and myeloid colony formation is believed not to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and myeloid colony formation is believed not to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and myeloid colony formation is not able to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and myeloid colony formation is not able to be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and myeloid colony formation is not blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and myeloid colony formation is not blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and pre-incubation of the antibodies with the phosphopeptide does not block labeling, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the action of a postulated repressor can not be blocked by Alanine, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the action of a postulated repressor is believed not to be blocked by Alanine, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the action of a postulated repressor is not able to be blocked by Alanine, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the action of a postulated repressor is not blocked by Alanine, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Alanine has not blocked the action of a postulated repressor, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Tagetin has not blocked RNA polymerase during elongation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and antibodies to RAP1 has not blocked merozoite invasion in vitro, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation has not blocked myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation has not blocked myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and pre-incubation of the antibodies with the phosphopeptide has not blocked labeling, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Alanine will not block the action of a postulated repressor, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Alanine</arg>
                    <arg n="1">the action of a postulated repressor</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Tagetin will not block RNA polymerase during elongation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and antibodies to RAP1 will not block merozoite invasion in vitro, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation will not block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation will not block myeloid colony formation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and pre-incubation of the antibodies with the phosphopeptide will not block labeling, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>RNA polymerase during elongation can be blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>RNA polymerase during elongation has been blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>RNA polymerase during elongation is blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>RNA polymerase during elongation was blocked by Tagetin.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>Tagetin blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>Tagetin blocks RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>Tagetin can block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>Tagetin can have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>Tagetin could block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>Tagetin could have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>Tagetin has blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>Tagetin is able to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>Tagetin is believed to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>Tagetin is thought to act as an inducer to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>Tagetin may block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>Tagetin may have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>Tagetin might block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>Tagetin might have blocked RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>Tagetin was able to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>Tagetin was believed to block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>Tagetin will block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>Tagetin would block RNA polymerase during elongation.</text>
                    <arg n="0">Tagetin</arg>
                    <arg n="1">RNA polymerase during elongation</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>antibodies to RAP1 blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>antibodies to RAP1 blocks merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>antibodies to RAP1 can block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>antibodies to RAP1 can have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>antibodies to RAP1 could block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>antibodies to RAP1 could have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>antibodies to RAP1 has blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>antibodies to RAP1 is able to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>antibodies to RAP1 is believed to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>antibodies to RAP1 is more specific for distinguishing between different RNA polymerases because it blocked merozoite invasion in vitro (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>antibodies to RAP1 is more specific for distinguishing between different RNA polymerases because it blocks merozoite invasion in vitro (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>antibodies to RAP1 is more specific for distinguishing between different RNA polymerases because it can block merozoite invasion in vitro (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>antibodies to RAP1 is more specific for distinguishing between different RNA polymerases because it is able to block merozoite invasion in vitro (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>antibodies to RAP1 is more specific for distinguishing between different RNA polymerases because it may blocks merozoite invasion in vitro (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>antibodies to RAP1 is more specific for distinguishing between different RNA polymerases because merozoite invasion in vitro can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>antibodies to RAP1 is more specific for distinguishing between different RNA polymerases because merozoite invasion in vitro is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>antibodies to RAP1 is more specific for distinguishing between different RNA polymerases because merozoite invasion in vitro is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>antibodies to RAP1 is more specific for distinguishing between different RNA polymerases because merozoite invasion in vitro was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>antibodies to RAP1 is thought to act as an inducer to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>antibodies to RAP1 may block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>antibodies to RAP1 may have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>antibodies to RAP1 might block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>antibodies to RAP1 might have blocked merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>antibodies to RAP1 was able to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>antibodies to RAP1 was believed to block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>antibodies to RAP1 will block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>antibodies to RAP1 would block merozoite invasion in vitro.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>elevation of GR by 14-3-3eta can be blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>elevation of GR by 14-3-3eta has been blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>elevation of GR by 14-3-3eta is blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>elevation of GR by 14-3-3eta was blocked by inhibition of translation.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation can block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation can have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation could block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation could have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is believed to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is more specific for distinguishing between different RNA polymerases because it blocked myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is more specific for distinguishing between different RNA polymerases because it blocks myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is more specific for distinguishing between different RNA polymerases because it can block myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is more specific for distinguishing between different RNA polymerases because it is able to block myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is more specific for distinguishing between different RNA polymerases because it may blocks myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is more specific for distinguishing between different RNA polymerases because myeloid colony formation can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is more specific for distinguishing between different RNA polymerases because myeloid colony formation is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is more specific for distinguishing between different RNA polymerases because myeloid colony formation is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is more specific for distinguishing between different RNA polymerases because myeloid colony formation was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation is thought to act as an inducer to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation may block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation may have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation might block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation might have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation was able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation was believed to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation would block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation blocks myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation can block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation can have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation could block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation could have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation has blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is believed to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is more specific for distinguishing between different RNA polymerases because it blocked myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is more specific for distinguishing between different RNA polymerases because it blocks myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is more specific for distinguishing between different RNA polymerases because it can block myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is more specific for distinguishing between different RNA polymerases because it is able to block myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is more specific for distinguishing between different RNA polymerases because it may blocks myeloid colony formation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is more specific for distinguishing between different RNA polymerases because myeloid colony formation can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is more specific for distinguishing between different RNA polymerases because myeloid colony formation is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is more specific for distinguishing between different RNA polymerases because myeloid colony formation is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is more specific for distinguishing between different RNA polymerases because myeloid colony formation was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation is thought to act as an inducer to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation may block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation may have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation might block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation might have blocked myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation was able to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation was believed to block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation will block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation would block myeloid colony formation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>inhibition of translation blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>inhibition of translation blocks elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>inhibition of translation can block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>inhibition of translation can have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>inhibition of translation could block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>inhibition of translation could have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>inhibition of translation has blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>inhibition of translation is able to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>inhibition of translation is believed to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>inhibition of translation is more specific for distinguishing between different RNA polymerases because elevation of GR by 14-3-3eta can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>inhibition of translation is more specific for distinguishing between different RNA polymerases because elevation of GR by 14-3-3eta is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>inhibition of translation is more specific for distinguishing between different RNA polymerases because elevation of GR by 14-3-3eta is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>inhibition of translation is more specific for distinguishing between different RNA polymerases because elevation of GR by 14-3-3eta was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>inhibition of translation is more specific for distinguishing between different RNA polymerases because it blocked elevation of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>inhibition of translation is more specific for distinguishing between different RNA polymerases because it blocks elevation of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>inhibition of translation is more specific for distinguishing between different RNA polymerases because it can block elevation of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>inhibition of translation is more specific for distinguishing between different RNA polymerases because it is able to block elevation of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>inhibition of translation is more specific for distinguishing between different RNA polymerases because it may blocks elevation of GR by 14-3-3eta (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>inhibition of translation is thought to act as an inducer to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>inhibition of translation may block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>inhibition of translation may have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>inhibition of translation might block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>inhibition of translation might have blocked elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>inhibition of translation was able to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>inhibition of translation was believed to block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>inhibition of translation will block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>inhibition of translation would block elevation of GR by 14-3-3eta.</text>
                    <arg n="0">inhibition of translation</arg>
                    <arg n="1">elevation of GR by 14-3-3eta</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>labeling can be blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>labeling has been blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>labeling is blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>labeling was blocked by pre-incubation of the antibodies with the phosphopeptide.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>merozoite invasion in vitro can be blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>merozoite invasion in vitro has been blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>merozoite invasion in vitro is blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>merozoite invasion in vitro was blocked by antibodies to RAP1.</text>
                    <arg n="0">antibodies to RAP1</arg>
                    <arg n="1">merozoite invasion in vitro</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>myeloid colony formation can be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>myeloid colony formation can be blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>myeloid colony formation has been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>myeloid colony formation has been blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>myeloid colony formation is blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>myeloid colony formation is blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>myeloid colony formation was blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>myeloid colony formation was blocked by inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation.</text>
                    <arg n="0">inhibition of PU.1 function in human CD34+ progenitors prior to this-upregulation</arg>
                    <arg n="1">myeloid colony formation</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>pre-incubation of the antibodies with the phosphopeptide blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>pre-incubation of the antibodies with the phosphopeptide blocks labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>pre-incubation of the antibodies with the phosphopeptide can block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>pre-incubation of the antibodies with the phosphopeptide can have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>pre-incubation of the antibodies with the phosphopeptide could block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>pre-incubation of the antibodies with the phosphopeptide could have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>pre-incubation of the antibodies with the phosphopeptide has blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>pre-incubation of the antibodies with the phosphopeptide is able to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>pre-incubation of the antibodies with the phosphopeptide is believed to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>pre-incubation of the antibodies with the phosphopeptide is more specific for distinguishing between different RNA polymerases because it blocked labeling (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>pre-incubation of the antibodies with the phosphopeptide is more specific for distinguishing between different RNA polymerases because it blocks labeling (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>pre-incubation of the antibodies with the phosphopeptide is more specific for distinguishing between different RNA polymerases because it can block labeling (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>pre-incubation of the antibodies with the phosphopeptide is more specific for distinguishing between different RNA polymerases because it is able to block labeling (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>pre-incubation of the antibodies with the phosphopeptide is more specific for distinguishing between different RNA polymerases because it may blocks labeling (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>pre-incubation of the antibodies with the phosphopeptide is more specific for distinguishing between different RNA polymerases because labeling can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>pre-incubation of the antibodies with the phosphopeptide is more specific for distinguishing between different RNA polymerases because labeling is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>pre-incubation of the antibodies with the phosphopeptide is more specific for distinguishing between different RNA polymerases because labeling is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>pre-incubation of the antibodies with the phosphopeptide is more specific for distinguishing between different RNA polymerases because labeling was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>pre-incubation of the antibodies with the phosphopeptide is thought to act as an inducer to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>pre-incubation of the antibodies with the phosphopeptide may block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>pre-incubation of the antibodies with the phosphopeptide may have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>pre-incubation of the antibodies with the phosphopeptide might block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>pre-incubation of the antibodies with the phosphopeptide might have blocked labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>pre-incubation of the antibodies with the phosphopeptide was able to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>pre-incubation of the antibodies with the phosphopeptide was believed to block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>pre-incubation of the antibodies with the phosphopeptide will block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>pre-incubation of the antibodies with the phosphopeptide would block labeling.</text>
                    <arg n="0">pre-incubation of the antibodies with the phosphopeptide</arg>
                    <arg n="1">labeling</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>14-3-3eta functions can be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>14-3-3eta functions has been blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>14-3-3eta functions is blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>14-3-3eta functions was blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Both RAP1 and 2 are important vaccine candidates because 14-3-3eta functions is shown to be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Both RAP1 and 2 are important vaccine candidates because 14-3-3eta functions is shown to have been blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Both RAP1 and 2 are important vaccine candidates because 14-3-3eta functions was shown to be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Both RAP1 and 2 are important vaccine candidates because 14-3-3eta functions was shown to have been blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>Both RAP1 and 2 are important vaccine candidates because Mutations at the 3 splice site are shown to be able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Both RAP1 and 2 are important vaccine candidates because Mutations at the 3 splice site are shown to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Both RAP1 and 2 are important vaccine candidates because Mutations at the 3 splice site are shown to have blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>Both RAP1 and 2 are important vaccine candidates because Mutations at the 3 splice site have been shown to be able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>Both RAP1 and 2 are important vaccine candidates because Mutations at the 3 splice site have been shown to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>Both RAP1 and 2 are important vaccine candidates because Mutations at the 3 splice site have been shown to have blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>Both RAP1 and 2 are important vaccine candidates because a positive regulator in the glucocorticoid signal pathway are shown to be able to block the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>Both RAP1 and 2 are important vaccine candidates because a positive regulator in the glucocorticoid signal pathway are shown to block the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>Both RAP1 and 2 are important vaccine candidates because a positive regulator in the glucocorticoid signal pathway are shown to have blocked the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>Both RAP1 and 2 are important vaccine candidates because a positive regulator in the glucocorticoid signal pathway have been shown to be able to block the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>Both RAP1 and 2 are important vaccine candidates because a positive regulator in the glucocorticoid signal pathway have been shown to block the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>Both RAP1 and 2 are important vaccine candidates because a positive regulator in the glucocorticoid signal pathway have been shown to have blocked the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>Both RAP1 and 2 are important vaccine candidates because agrin-induced AChR clustering and phosphorylation is shown to be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>Both RAP1 and 2 are important vaccine candidates because agrin-induced AChR clustering and phosphorylation is shown to have been blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>Both RAP1 and 2 are important vaccine candidates because agrin-induced AChR clustering and phosphorylation was shown to be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>Both RAP1 and 2 are important vaccine candidates because agrin-induced AChR clustering and phosphorylation was shown to have been blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions can be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions could be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions has been blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions is believed to be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions is blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions may be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions might be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions was believed to be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions was blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions will be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that 14-3-3eta functions would be blocked by the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Mutations at the 3 splice site are able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Mutations at the 3 splice site block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Mutations at the 3 splice site blocked step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Mutations at the 3 splice site can block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Mutations at the 3 splice site may block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that Mutations at the 3 splice site were able to block step II (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that a positive regulator in the glucocorticoid signal pathway are able to block the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that a positive regulator in the glucocorticoid signal pathway block the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that a positive regulator in the glucocorticoid signal pathway blocked the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that a positive regulator in the glucocorticoid signal pathway can block the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that a positive regulator in the glucocorticoid signal pathway may block the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that a positive regulator in the glucocorticoid signal pathway were able to block the degradation of GR and inducing an elevation of GR (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation can be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation could be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation has been blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation is believed to be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation is blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation may be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation might be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation was believed to be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation was blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation will be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that agrin-induced AChR clustering and phosphorylation would be blocked by staurosporine (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that staurosporine are able to block agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that staurosporine block agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that staurosporine blocked agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that staurosporine can block agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that staurosporine may block agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that staurosporine were able to block agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II can be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II could be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II has been blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II is believed to be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II is blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II may be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II might be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II was believed to be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II was blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II will be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that step II would be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR are able to block 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR block 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR blocked 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR can be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR can block 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR could be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR has been blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR is believed to be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR is blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR may be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR may block 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR might be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR was believed to be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR was blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR were able to block 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR will be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>Both RAP1 and 2 are important vaccine candidates because it has been shown that the degradation of GR and inducing an elevation of GR would be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>Both RAP1 and 2 are important vaccine candidates because staurosporine are shown to be able to block agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>Both RAP1 and 2 are important vaccine candidates because staurosporine are shown to block agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>Both RAP1 and 2 are important vaccine candidates because staurosporine are shown to have blocked agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>Both RAP1 and 2 are important vaccine candidates because staurosporine have been shown to be able to block agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>Both RAP1 and 2 are important vaccine candidates because staurosporine have been shown to block agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>Both RAP1 and 2 are important vaccine candidates because staurosporine have been shown to have blocked agrin-induced AChR clustering and phosphorylation (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>Both RAP1 and 2 are important vaccine candidates because step II is shown to be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>Both RAP1 and 2 are important vaccine candidates because step II is shown to have been blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Both RAP1 and 2 are important vaccine candidates because step II was shown to be blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Both RAP1 and 2 are important vaccine candidates because step II was shown to have been blocked by Mutations at the 3 splice site (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR are shown to be able to block 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR are shown to block 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR are shown to have blocked 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR have been shown to be able to block 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR have been shown to block 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR have been shown to have blocked 14-3-3eta functions (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR is shown to be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR is shown to have been blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR was shown to be blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>Both RAP1 and 2 are important vaccine candidates because the degradation of GR and inducing an elevation of GR was shown to have been blocked by a positive regulator in the glucocorticoid signal pathway (Schofield et al., 1986; Harnyuttanakorn et al., 1992; Howard et al., 1998a).</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since 14-3-3eta functions can be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since 14-3-3eta functions is able to be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since 14-3-3eta functions is believed to be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since 14-3-3eta functions is blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Mutations at the 3 splice site blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Mutations at the 3 splice site blocks step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Mutations at the 3 splice site can block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Mutations at the 3 splice site can have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Mutations at the 3 splice site have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Mutations at the 3 splice site is able to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Mutations at the 3 splice site may block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Mutations at the 3 splice site may have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since Mutations at the 3 splice site will block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since a positive regulator in the glucocorticoid signal pathway blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since a positive regulator in the glucocorticoid signal pathway blocks the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since a positive regulator in the glucocorticoid signal pathway can block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since a positive regulator in the glucocorticoid signal pathway can have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since a positive regulator in the glucocorticoid signal pathway have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since a positive regulator in the glucocorticoid signal pathway is able to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since a positive regulator in the glucocorticoid signal pathway may block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since a positive regulator in the glucocorticoid signal pathway may have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since a positive regulator in the glucocorticoid signal pathway will block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since agrin-induced AChR clustering and phosphorylation can be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since agrin-induced AChR clustering and phosphorylation is able to be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since agrin-induced AChR clustering and phosphorylation is believed to be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since agrin-induced AChR clustering and phosphorylation is blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since staurosporine blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since staurosporine blocks agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since staurosporine can block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since staurosporine can have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since staurosporine have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since staurosporine is able to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since staurosporine may block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since staurosporine may have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since staurosporine will block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since step II can be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since step II is able to be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since step II is believed to be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since step II is blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR blocks 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR can be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR can block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR can have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR is able to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR is able to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR is believed to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR is blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR may block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR may have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>Labeling with antibodies to the Y553 phosphopeptide is specific since the degradation of GR and inducing an elevation of GR will block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since 14-3-3eta functions could be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since 14-3-3eta functions has been blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since 14-3-3eta functions was able to be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since 14-3-3eta functions was believed to be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since 14-3-3eta functions was blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Mutations at the 3 splice site could block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Mutations at the 3 splice site could have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Mutations at the 3 splice site might block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Mutations at the 3 splice site might have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Mutations at the 3 splice site was able to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Mutations at the 3 splice site would block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since Mutations at the 3 splice site would have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since a positive regulator in the glucocorticoid signal pathway could block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since a positive regulator in the glucocorticoid signal pathway could have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since a positive regulator in the glucocorticoid signal pathway might block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since a positive regulator in the glucocorticoid signal pathway might have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since a positive regulator in the glucocorticoid signal pathway was able to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since a positive regulator in the glucocorticoid signal pathway would block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since a positive regulator in the glucocorticoid signal pathway would have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since agrin-induced AChR clustering and phosphorylation could be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since agrin-induced AChR clustering and phosphorylation has been blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since agrin-induced AChR clustering and phosphorylation was able to be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since agrin-induced AChR clustering and phosphorylation was believed to be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since agrin-induced AChR clustering and phosphorylation was blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since staurosporine could block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since staurosporine could have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since staurosporine might block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since staurosporine might have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since staurosporine was able to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since staurosporine would block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since staurosporine would have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since step II could be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since step II has been blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since step II was able to be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since step II was believed to be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since step II was blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR could be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR could block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR could have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR has been blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR might block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR might have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR was able to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR was able to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR was believed to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR was blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR would block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>Labeling with antibodies to the Y553 phosphopeptide was specific since the degradation of GR and inducing an elevation of GR would have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>Mutations at the 3 splice site blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>Mutations at the 3 splice site blocks step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>Mutations at the 3 splice site can block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>Mutations at the 3 splice site can have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>Mutations at the 3 splice site could block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>Mutations at the 3 splice site could have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>Mutations at the 3 splice site has blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>Mutations at the 3 splice site is able to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>Mutations at the 3 splice site is believed to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>Mutations at the 3 splice site is more specific for distinguishing between different RNA polymerases because it blocked step II (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>Mutations at the 3 splice site is more specific for distinguishing between different RNA polymerases because it blocks step II (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>Mutations at the 3 splice site is more specific for distinguishing between different RNA polymerases because it can block step II (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>Mutations at the 3 splice site is more specific for distinguishing between different RNA polymerases because it is able to block step II (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>Mutations at the 3 splice site is more specific for distinguishing between different RNA polymerases because it may blocks step II (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>Mutations at the 3 splice site is more specific for distinguishing between different RNA polymerases because step II can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>Mutations at the 3 splice site is more specific for distinguishing between different RNA polymerases because step II is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>Mutations at the 3 splice site is more specific for distinguishing between different RNA polymerases because step II is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>Mutations at the 3 splice site is more specific for distinguishing between different RNA polymerases because step II was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>Mutations at the 3 splice site is thought to act as an inducer to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>Mutations at the 3 splice site may block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>Mutations at the 3 splice site may have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>Mutations at the 3 splice site might block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>Mutations at the 3 splice site might have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>Mutations at the 3 splice site was able to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>Mutations at the 3 splice site was believed to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>Mutations at the 3 splice site will block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>Mutations at the 3 splice site would block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and 14-3-3eta functions can be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and 14-3-3eta functions is believed to be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and 14-3-3eta functions is blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and 14-3-3eta functions may be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and 14-3-3eta functions will be blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site blocks step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site can block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site has blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site is able to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site is believed to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site is believed to have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site is proven to block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site is proven to have blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site will block step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway blocks the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway can block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway has blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway is able to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway is believed to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway is believed to have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway is proven to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway is proven to have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway will block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and agrin-induced AChR clustering and phosphorylation can be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and agrin-induced AChR clustering and phosphorylation is believed to be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and agrin-induced AChR clustering and phosphorylation is blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and agrin-induced AChR clustering and phosphorylation may be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and agrin-induced AChR clustering and phosphorylation will be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine blocks agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine can block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine has blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine is able to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine is believed to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine is believed to have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine is proven to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine is proven to have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine will block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and step II can be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and step II is believed to be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and step II is blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and step II may be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and step II will be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR blocks 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR can be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR can block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR has blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR is able to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR is believed to be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR is believed to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR is believed to have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR is blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR is proven to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR is proven to have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR may be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR will be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR will block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and 14-3-3eta functions has been blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and 14-3-3eta functions was blocked by the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and Mutations at the 3 splice site has blocked step II.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and a positive regulator in the glucocorticoid signal pathway has blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and agrin-induced AChR clustering and phosphorylation has been blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and agrin-induced AChR clustering and phosphorylation was blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and staurosporine has blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and step II has been blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and step II was blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR has been blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR has blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>PU.1 was upregulated early during commitment of multipotential progenitors to the myeloid lineages and the degradation of GR and inducing an elevation of GR was blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Mutations at the 3 splice site can not block step II, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Mutations at the 3 splice site is not able to block step II, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and a positive regulator in the glucocorticoid signal pathway can not block the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and a positive regulator in the glucocorticoid signal pathway is not able to block the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and staurosporine can not block agrin-induced AChR clustering and phosphorylation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and staurosporine is not able to block agrin-induced AChR clustering and phosphorylation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR can not block 14-3-3eta functions, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>Proteasomal inhibition can not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR is not able to block 14-3-3eta functions, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Mutations at the 3 splice site did not block step II, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and a positive regulator in the glucocorticoid signal pathway did not block the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and staurosporine did not block agrin-induced AChR clustering and phosphorylation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>Proteasomal inhibition did not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR did not block 14-3-3eta functions, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and 14-3-3eta functions can not be blocked by the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and 14-3-3eta functions is believed not to be blocked by the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and 14-3-3eta functions is not able to be blocked by the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and 14-3-3eta functions is not blocked by the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Mutations at the 3 splice site does not block step II, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and a positive regulator in the glucocorticoid signal pathway does not block the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and agrin-induced AChR clustering and phosphorylation can not be blocked by staurosporine, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and agrin-induced AChR clustering and phosphorylation is believed not to be blocked by staurosporine, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and agrin-induced AChR clustering and phosphorylation is not able to be blocked by staurosporine, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and agrin-induced AChR clustering and phosphorylation is not blocked by staurosporine, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and staurosporine does not block agrin-induced AChR clustering and phosphorylation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and step II can not be blocked by Mutations at the 3 splice site, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and step II is believed not to be blocked by Mutations at the 3 splice site, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and step II is not able to be blocked by Mutations at the 3 splice site, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and step II is not blocked by Mutations at the 3 splice site, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR can not be blocked by a positive regulator in the glucocorticoid signal pathway, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR does not block 14-3-3eta functions, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR is believed not to be blocked by a positive regulator in the glucocorticoid signal pathway, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR is not able to be blocked by a positive regulator in the glucocorticoid signal pathway, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>Proteasomal inhibition does not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR is not blocked by a positive regulator in the glucocorticoid signal pathway, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Mutations at the 3 splice site has not blocked step II, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and a positive regulator in the glucocorticoid signal pathway has not blocked the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and staurosporine has not blocked agrin-induced AChR clustering and phosphorylation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>Proteasomal inhibition has not induced any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR has not blocked 14-3-3eta functions, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and Mutations at the 3 splice site will not block step II, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and a positive regulator in the glucocorticoid signal pathway will not block the degradation of GR and inducing an elevation of GR, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and staurosporine will not block agrin-induced AChR clustering and phosphorylation, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>Proteasomal inhibition will not induce any synergistic effect on the 14-3-3eta-induced increase in GR in response to glucocorticoid, and the degradation of GR and inducing an elevation of GR will not block 14-3-3eta functions, indicating that 14-3-3eta induces stabilization of GR.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>a positive regulator in the glucocorticoid signal pathway blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>a positive regulator in the glucocorticoid signal pathway blocks the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>a positive regulator in the glucocorticoid signal pathway can block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>a positive regulator in the glucocorticoid signal pathway can have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>a positive regulator in the glucocorticoid signal pathway could block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>a positive regulator in the glucocorticoid signal pathway could have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>a positive regulator in the glucocorticoid signal pathway has blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>a positive regulator in the glucocorticoid signal pathway is able to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>a positive regulator in the glucocorticoid signal pathway is believed to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for distinguishing between different RNA polymerases because it blocked the degradation of GR and inducing an elevation of GR (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for distinguishing between different RNA polymerases because it blocks the degradation of GR and inducing an elevation of GR (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for distinguishing between different RNA polymerases because it can block the degradation of GR and inducing an elevation of GR (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for distinguishing between different RNA polymerases because it is able to block the degradation of GR and inducing an elevation of GR (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for distinguishing between different RNA polymerases because it may blocks the degradation of GR and inducing an elevation of GR (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for distinguishing between different RNA polymerases because the degradation of GR and inducing an elevation of GR can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for distinguishing between different RNA polymerases because the degradation of GR and inducing an elevation of GR is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for distinguishing between different RNA polymerases because the degradation of GR and inducing an elevation of GR is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>a positive regulator in the glucocorticoid signal pathway is more specific for distinguishing between different RNA polymerases because the degradation of GR and inducing an elevation of GR was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>a positive regulator in the glucocorticoid signal pathway is thought to act as an inducer to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>a positive regulator in the glucocorticoid signal pathway may block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>a positive regulator in the glucocorticoid signal pathway may have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>a positive regulator in the glucocorticoid signal pathway might block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>a positive regulator in the glucocorticoid signal pathway might have blocked the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>a positive regulator in the glucocorticoid signal pathway was able to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>a positive regulator in the glucocorticoid signal pathway was believed to block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>a positive regulator in the glucocorticoid signal pathway will block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>a positive regulator in the glucocorticoid signal pathway would block the degradation of GR and inducing an elevation of GR.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>agrin-induced AChR clustering and phosphorylation can be blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>agrin-induced AChR clustering and phosphorylation has been blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>agrin-induced AChR clustering and phosphorylation is blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>agrin-induced AChR clustering and phosphorylation was blocked by staurosporine.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>staurosporine blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>staurosporine blocks agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>staurosporine can block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>staurosporine can have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>staurosporine could block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>staurosporine could have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>staurosporine has blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>staurosporine is able to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>staurosporine is believed to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>staurosporine is more specific for distinguishing between different RNA polymerases because agrin-induced AChR clustering and phosphorylation can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>staurosporine is more specific for distinguishing between different RNA polymerases because agrin-induced AChR clustering and phosphorylation is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>staurosporine is more specific for distinguishing between different RNA polymerases because agrin-induced AChR clustering and phosphorylation is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>staurosporine is more specific for distinguishing between different RNA polymerases because agrin-induced AChR clustering and phosphorylation was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>staurosporine is more specific for distinguishing between different RNA polymerases because it blocked agrin-induced AChR clustering and phosphorylation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>staurosporine is more specific for distinguishing between different RNA polymerases because it blocks agrin-induced AChR clustering and phosphorylation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>staurosporine is more specific for distinguishing between different RNA polymerases because it can block agrin-induced AChR clustering and phosphorylation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>staurosporine is more specific for distinguishing between different RNA polymerases because it is able to block agrin-induced AChR clustering and phosphorylation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>staurosporine is more specific for distinguishing between different RNA polymerases because it may blocks agrin-induced AChR clustering and phosphorylation (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>staurosporine is thought to act as an inducer to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>staurosporine may block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>staurosporine may have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>staurosporine might block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>staurosporine might have blocked agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>staurosporine was able to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>staurosporine was believed to block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>staurosporine will block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>staurosporine would block agrin-induced AChR clustering and phosphorylation.</text>
                    <arg n="0">staurosporine</arg>
                    <arg n="1">agrin-induced AChR clustering and phosphorylation</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>step II can be blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>step II has been blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>step II is blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>step II was blocked by Mutations at the 3 splice site.</text>
                    <arg n="0">Mutations at the 3 splice site</arg>
                    <arg n="1">step II</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>the degradation of GR and inducing an elevation of GR blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>the degradation of GR and inducing an elevation of GR blocks 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>the degradation of GR and inducing an elevation of GR can be blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>the degradation of GR and inducing an elevation of GR can block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>the degradation of GR and inducing an elevation of GR can have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>the degradation of GR and inducing an elevation of GR could block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>the degradation of GR and inducing an elevation of GR could have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>the degradation of GR and inducing an elevation of GR has been blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>the degradation of GR and inducing an elevation of GR has blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>the degradation of GR and inducing an elevation of GR is able to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>the degradation of GR and inducing an elevation of GR is believed to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>the degradation of GR and inducing an elevation of GR is blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>the degradation of GR and inducing an elevation of GR is more specific for distinguishing between different RNA polymerases because 14-3-3eta functions can be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>the degradation of GR and inducing an elevation of GR is more specific for distinguishing between different RNA polymerases because 14-3-3eta functions is able to be blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>the degradation of GR and inducing an elevation of GR is more specific for distinguishing between different RNA polymerases because 14-3-3eta functions is blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>the degradation of GR and inducing an elevation of GR is more specific for distinguishing between different RNA polymerases because 14-3-3eta functions was blocked by it (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>the degradation of GR and inducing an elevation of GR is more specific for distinguishing between different RNA polymerases because it blocked 14-3-3eta functions (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>the degradation of GR and inducing an elevation of GR is more specific for distinguishing between different RNA polymerases because it blocks 14-3-3eta functions (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>the degradation of GR and inducing an elevation of GR is more specific for distinguishing between different RNA polymerases because it can block 14-3-3eta functions (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>the degradation of GR and inducing an elevation of GR is more specific for distinguishing between different RNA polymerases because it is able to block 14-3-3eta functions (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>the degradation of GR and inducing an elevation of GR is more specific for distinguishing between different RNA polymerases because it may blocks 14-3-3eta functions (Mathews and Durbin, 1994), i.e.its action is independent of different initiation factors.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>the degradation of GR and inducing an elevation of GR is thought to act as an inducer to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>the degradation of GR and inducing an elevation of GR may block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>the degradation of GR and inducing an elevation of GR may have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>the degradation of GR and inducing an elevation of GR might block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>the degradation of GR and inducing an elevation of GR might have blocked 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>the degradation of GR and inducing an elevation of GR was able to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>the degradation of GR and inducing an elevation of GR was believed to block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>the degradation of GR and inducing an elevation of GR was blocked by a positive regulator in the glucocorticoid signal pathway.</text>
                    <arg n="0">a positive regulator in the glucocorticoid signal pathway</arg>
                    <arg n="1">the degradation of GR and inducing an elevation of GR</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>the degradation of GR and inducing an elevation of GR will block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>the degradation of GR and inducing an elevation of GR would block 14-3-3eta functions.</text>
                    <arg n="0">the degradation of GR and inducing an elevation of GR</arg>
                    <arg n="1">14-3-3eta functions</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
